Orlance, Inc.
Seattle, WA Orlance, Inc.
- UEI
- KH6YJYH55G53
- CAGE
- 7PN99
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 401 Terry Ave N, Seattle, WA 98109, USA
- Website
- orlance.com
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
About Orlance, Inc.
Orlance, Inc. is a woman-owned small business located in Seattle, Washington, specializing in advanced vaccine technologies and delivery systems. The company has developed innovative gene gun technologies, specifically the MACH-1 platform, which enables efficient delivery of DNA and RNA vaccines directly into epidermal cells using high-pressure gas and gold microparticles. Registered in SAM.gov since 2016, Orlance, Inc. focuses on developing cutting-edge vaccine technologies that offer potential improvements over traditional vaccine delivery methods, including needle-free, pain-free administration and the ability to induce robust immune responses with significantly lower vaccine doses.
The company has secured multiple federal grants from the National Institute of Allergy and Infectious Diseases (NIAID) and the National Cancer Institute, focusing on developing advanced vaccine technologies for critical medical challenges. These grants include projects for a therapeutic nucleic acid vaccine targeting chronic hepatitis B in HIV/HBV co-infected individuals, an enhanced seasonal influenza vaccine, gene gun-delivered RNA vaccine research, and immunotherapeutic vaccines for melanoma. Orlance has also participated in sub-grant awards, such as collaborating with the University of North Carolina at Chapel Hill on developing an mRNA vaccine approach for treating peanut allergies. Their research consistently emphasizes innovative vaccine delivery technologies, particularly their MACH-1 gene gun platform, which can deliver room-temperature stable DNA and RNA vaccines with potential advantages in immunogenicity, stability, and targeted immune responses across various disease contexts.
Quick answers
What is Orlance, Inc.'s UEI?
Orlance, Inc.'s Unique Entity ID (UEI) in SAM.gov is KH6YJYH55G53.
What is Orlance, Inc.'s CAGE code?
Orlance, Inc.'s CAGE code is 7PN99.
What is Orlance, Inc.'s primary NAICS code?
Orlance, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Orlance, Inc. located?
Orlance, Inc.'s physical address in SAM.gov is 401 Terry Ave N, Seattle, WA 98109, USA.
Is Orlance, Inc. registered in SAM.gov?
Yes. Orlance, Inc.'s SAM.gov registration is active through February 22, 2027.
What is Orlance, Inc.'s most recent federal award?
Orlance, Inc.'s most recent federal grant award is Therapeutic nucleic acid vaccine for chronic hepatitis b in HIV/HBV CO-infected individuals - project summary over 300… (R41AI195068), from National Institute of Allergy and Infectious Diseases, on September 11, 2025.
On GovTribe
See Orlance, Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors